297 related articles for article (PubMed ID: 26311526)
1. PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer.
Owadally W; Hurt C; Timmins H; Parsons E; Townsend S; Patterson J; Hutcheson K; Powell N; Beasley M; Palaniappan N; Robinson M; Jones TM; Evans M
BMC Cancer; 2015 Aug; 15():602. PubMed ID: 26311526
[TBL] [Abstract][Full Text] [Related]
2. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
[TBL] [Abstract][Full Text] [Related]
3. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma.
Howard J; Masterson L; Dwivedi RC; Riffat F; Benson R; Jefferies S; Jani P; Tysome JR; Nutting C
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010963. PubMed ID: 27943254
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).
Bußmann L; Laban S; Wittekindt C; Stromberger C; Tribius S; Möckelmann N; Böttcher A; Betz CS; Klussmann JP; Budach V; Muenscher A; Busch CJ
BMC Cancer; 2020 Jul; 20(1):701. PubMed ID: 32727416
[TBL] [Abstract][Full Text] [Related]
5. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
[TBL] [Abstract][Full Text] [Related]
6. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
7. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.
Cramer JD; Ferris RL; Kim S; Duvvuri U
Oral Oncol; 2018 Dec; 87():170-176. PubMed ID: 30527235
[TBL] [Abstract][Full Text] [Related]
8. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar I; Rooney K; Roe JW; Patterson JM; Bernstein D; Tyler JM; Emson MA; Morden JP; Mertens K; Miles E; Beasley M; Roques T; Bhide SA; Newbold KL; Harrington KJ; Hall E; Nutting CM
BMC Cancer; 2016 Oct; 16(1):770. PubMed ID: 27716125
[TBL] [Abstract][Full Text] [Related]
9. Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development.
Hargreaves S; Beasley M; Hurt C; Jones TM; Evans M
Front Oncol; 2019; 9():936. PubMed ID: 31632901
[TBL] [Abstract][Full Text] [Related]
10. Controversies in Postoperative Irradiation of Oropharyngeal Cancer After Transoral Surgery.
Yom SS; Mallen-St Clair J; Ha PK
Surg Oncol Clin N Am; 2017 Jul; 26(3):357-370. PubMed ID: 28576176
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.
Nichols AC; Theurer J; Prisman E; Read N; Berthelet E; Tran E; Fung K; de Almeida JR; Bayley A; Goldstein DP; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Winquist E; Hammond JA; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Chen J; Corsten M; Johnson-Obaseki S; Eapen L; Odell M; Parker C; Wehrli B; Kwan K; Palma DA
Lancet Oncol; 2019 Oct; 20(10):1349-1359. PubMed ID: 31416685
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
13. The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients.
Smith RV; Schiff BA; Garg M; Haigentz M
Laryngoscope; 2015 Nov; 125 Suppl 10():S1-S15. PubMed ID: 26436491
[TBL] [Abstract][Full Text] [Related]
14. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
[TBL] [Abstract][Full Text] [Related]
15. ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas.
Beitler JJ; Quon H; Jones CU; Salama JK; Busse PM; Cooper JS; Koyfman SA; Ridge JA; Saba NF; Siddiqui F; Smith RV; Worden F; Yao M; Yom SS;
Head Neck; 2016 Sep; 38(9):1299-309. PubMed ID: 27330003
[TBL] [Abstract][Full Text] [Related]
16. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
[TBL] [Abstract][Full Text] [Related]
17. Transoral Resection of Human Papillomavirus (HPV)-Positive Squamous Cell Carcinoma of the Oropharynx: Outcomes with and Without Adjuvant Therapy.
Jackson RS; Sinha P; Zenga J; Kallogjeri D; Suko J; Martin E; Moore EJ; Haughey BH
Ann Surg Oncol; 2017 Nov; 24(12):3494-3501. PubMed ID: 28808988
[TBL] [Abstract][Full Text] [Related]
18. Preservation of swallowing in resected oral cavity squamous cell carcinoma: examining radiation volume effects (PRESERVE): study protocol for a randomized phase II trial.
Lang P; Contreras J; Kalman N; Paterson C; Bahig H; Billfalk-Kelly A; Brennan S; Rock K; Read N; Venkatesan V; Sathya J; Mendez LC; MacNeil SD; Nichols AC; Fung K; Mendez A; Winquist E; Kuruvilla S; Stewart P; Warner A; Mitchell S; Theurer JA; Palma DA
Radiat Oncol; 2020 Aug; 15(1):196. PubMed ID: 32795322
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
20. CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer.
Mehanna H; Gaunt P; Kong A; Hartley A; Sanghera P; Forster M; Sen M; Paleri V; Fong C; Geropantas D; Srinivasan D; Garikipati S; Moleron R; Casswell G; Aynsley E; Ward A; O'Toole L; Mirza A; Firth C; Humphreys I; Fulton-Lieuw T; Roques T; Nankivell P
Trials; 2024 Jan; 25(1):50. PubMed ID: 38221636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
